Back to Authors

Gutiérrez, Roberto-León

Mayo Clinic

Mayo Clinic

Citations 1

Lipotoxicity Induces β-cell Small Extracellular Vesicle–Mediated β-cell Dysfunction in Male Mice
Roy, Abhishek , Hoff, Alexandra, Ariyaratne, Gallage, Tahawi, M H D Noor, Rajagopalan, Kamalnath Sankaran, Brown, Matthew , Omori, Kazuno , Lewis-Brinkman, Sean , Nguyen, Thanh, Soto-González, Alondra , Matveyenko, Aleksey V. , Javeed, Naureen , Her, Tracy K. , Gutiérrez, Roberto-León, Peterson, Quinn P. , Javeed, Naureen , Roy, Abhishek, Gutiérrez, Roberto-León, TAHAWI, MHD NOOR

Endocrinology | April 3, 2025 | Volume: 166 | Issue: 5 | Pages: No page available

10.1210/endocr/bqaf067 Get It

Abstract Chronically elevated circulating excess free fatty acids (ie, lipotoxicity) is a pathological process implicated in several metabolic disorders, including obesity-driven type 2 diabetes (T2D). Lipotoxicity exerts detrimental effects on pancreatic islet β-cells by reducing glucose-stimulated insulin secretion (GSIS), altering β-cell transcriptional identity, and promoting apoptosis. While β-cell-derived small extracellular vesicles (sEV) have been shown to contribute to β-cell failure in T2D, their specific role in lipotoxicity-mediated β-cell failure remains to be elucidated. In this work, we demonstrate that lipotoxicity enhances the release of sEVs from β-cells, which exhibit altered proteomic and lipidomic profiles. These palmitate (PAL)-exposed extracellular vesicles (EVs) induce β-cell dysfunction in healthy mouse and human islets and trigger significant islet transcriptional changes, including the upregulation of genes associated with the TGFβ/Smad3 pathway, as noted by RNA sequencing. Importantly, pharmacological inhibition of the TGFβI/II receptor improved PAL EV-induced β-cell dysfunction, underscoring their involvement in activating the TGFβ/Smad3 pathway during this process. We have comprehensively characterized lipotoxic β-cell sEVs and implicated their role in inducing β-cell functional failure in T2D. These findings highlight potential avenues for therapeutic interventions targeting sEV-mediated pathways to preserve β-cell health in metabolic disorders.